ORACLE is a new genetic test that combines machine learning with our understanding of tumour evolution to distinguish high- and low-risk lung tumours; it is also applicable to other tumours. This technology was developed by CRUK-funded scientists as part of the TRACERx study and was featured on the front cover of Nature Medicine. The underlying ORACLE methodology also has broader applicability for identifying biomarker signatures for prognostication in other cancer-types and predicting response to therapy (both targeted and immuno-oncology drugs).
You are here
All Licensing Opportunities
The BEST 2/3 Trial images are a database of clinically-linked digitised pathology slides, generated during the BEST 2 and and BEST 3 clinical trials. (See https://www.mrc-cu.cam.ac.uk/research/rebecca-fitzgerald/clinical-studies/BEST2Folder and https://www.mrc-cu.cam.ac.uk/research/rebecca-fitzgerald/clinical-studies/BEST3, respectively.) These trials were aimed at testing the feasibility of a new sampling method known as the Cytosponge. The Cytosponge is pill on a string which dissolves to release a sponge that can then be removed to gather samples from the oesophagus, and it has proven to be a successful alternative to endoscopy testing for patients at high risk of developing oesophageal cancer. During these trials, 3350 patient samples were collected and stained using standard H&E techniques, with additional staining for oesophageal cancer-related biomarker TFF3, and they were subsequently digitised. In addition to the digitised slides, biopsy results and the outcomes of complementary endoscopy testing can be provided upon approval from our clinical collaborator. We would be happy to discuss non-exclusive licensing of these assets with companies in the digital pathology space or other related areas.
In collaboration with Universities of Oxford and Leicester our CRUK-AstraZeneca Antibody Alliance Laboratory has developed a first-in-class, inhibitory antibody specific for human ARG2.
Licensing/collaborative opportunity around unique FcɣR-independent “super-agonistic” 4-IBB mABs containing a propriety hinge technology that promotes both CD8+ T cell activation and the depletion of intratumoral Treg cells.
CRUK has developed a potent, selective and orally bioavailable series of small molecules inhibiting glutaminase (GLS), with superior developability. We are seeking a co-development partner to support key in vivo data and drive rapid progression into clinical trials.
AZD3965 is a Phase 2 ready, first-in-class oral and highly selective inhibitor of MCT-1 that has shown promising signs of efficacy in early phase clinical trials in DLBCL. Initially developed by AstraZeneca, CRUK now holds exclusive rights to the programme. We are seeking a partner for out-licensing, with the opportunity to leverage the CRUK network to support further clinical development.
The Cox-2 Inflammatory Signature is a novel pan-cancer immuno-oncology predictive biomarker with strong proof of concept data on overall patient survival predictions across various malignancies.
mutREAD is a novel DNA sequencing method that measures the presence of mutational signatures in all types of clinical and biological samples. Its unique and powerful features are expected to facilitate the widespread development and application of mutational signatures in cancer.
We are seeking a commercial partner interested in pursuing the co-development or licensing of our imaging tracer 18F-FPIA.
CRUK is seeking a partner to collaborate on a proprietary technology better able to identify mutational patterns in cancer genomes for patient stratification.